mt1 melanotan 1 vs. 2: My Summer Journey & Real Results MT1 (Melanotan 1) Dosing: Clinical

2 , e38 (2013)

Nevertheless, the use of APAP in babies and young children, which was a relatively uncommon occurrence half a century ago, is now extremely common.One potential argument that APAP cannot cause ASD is that the rising rates of ASD over time are, at least in part, a consequence of changing diagnostic criteria, increased awareness, and other factors (discussed by co-author CDN and colleagues [35])

Potential benefits: Extends beyond 30 days Convenient pre-measured doses Significant risks: Ice crystal formation can damage peptide structure Unknown potency loss during freezing/thawing No clinical data supporting this practice Recommendation: Not advised

Patricia Brubaker, Ph.D., F.R.S.C., F.C.A.H.S